Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc. is a clinical stage biopharmaceutical company that develops treatments for rare disorders.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Rocket Pharmaceuticals' stock with a target price of $45.23, indicating strong growth potential.
Financial Health
Rocket Pharmaceuticals is showing strong financial performance with healthy cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RCKT
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketOrphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketThrill & Excitement Fund
Ready for an investing adventure? This collection features carefully selected stocks with explosive growth potential. Our professional analysts have identified companies at the cutting edge of space tourism, biotech breakthroughs, and digital gaming — all poised to potentially redefine their industries.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Progress Watch
Clinical readouts are primary value drivers; positive trial data can change valuation quickly, though outcomes are uncertain and timelines may shift.
Gene‑therapy Focus
Specialises in gene therapies for rare inherited diseases, an area with high scientific promise and distinct regulatory and manufacturing challenges.
Partnerships And Catalysts
Collaborations or licensing deals can de‑risk programmes and provide funding, but prospective investors should weigh news‑driven volatility and financing needs.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
